«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 14

Page:

2570-2573

Research Field:

Publishing date:

Info

Title:

Relationship between genetic polymorphism of X-ray repair cross-complementing group 1(XRCC1) and clinical outcomes of advanced gastric cancer receiving oxaliplatin plus capecitabine chemotherapy

Author(s):

HAN Lei¹; DONG Ningning²

1.Department of Oncology,Affiliated Hospital of Jining Medical University,Shandong Jining 272000,China；2.Department of Gastroenterology,Beijing Friendship Hospital,Capital Medical University/National Clinical Research Center of Gastrointestinal Disease/State Key Laboratory for Digestive Diseases/Beijing Digestive Disease Center/Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases,Beijing 100050,China.

Keywords:

advanced gastric cancer; X-ray repair cross-complementing group 1; genetic polymorphism; chemotherapy

PACS:

R735.2

DOI:

10.3969/j.issn.1672-4992.2024.14.013

Abstract:

Objective:To discuss the relationship between X-ray repair cross-complementing group 1 (XRCC1) gene polymorphism and clinical outcomes,time to progression of advanced gastric cancer receiving oxaliplatin plus capecitabine chemotherapy (XELOX regimen).Methods:A total of 110 patients with advanced gastric cancer were retrospectively enrolled.All patients received oxaliplatin plus capecitabine chemotherapy.XRCC1 genotype was obtained by matrix-assisted laser desorption ionization time-of-flightmass spectrometry.The relationship between the clinicopathological features of patients and genetic typing of XRCC1 rs25487 and objective response rate (ORR) and progression-free survival(PFS) was analyzed.Results:Among these enrolled patients,49 cases (44.5%) carried XRCC1 rs25487 GG genotype,52 patients (47.3%) AG genotype,and 9 patients (8.2%) AA genotype.GG genotype carriers had a higher ORR than AG/AA genotype carriers (53.1% vs 37.7%，P=0.107).Compared with AG/AA genotype carriers,GG genotype carriers showed statistically longer PFS［6.3 months (95%CI：5.7~6.9) vs 5.0 months (95%CI：4.4~5.6)，P=0.049)］.None of the clinicopathological characteristics was associated with ORR,whereas,tumor differentiation and TNM stage were related to PFS (P＜0.05).Multivariate analysis showed that tumor differentiation,TNM stage and XRCC1 rs25487 genotype were independent prognostic factors of PFS.Conclusion:XRCC1 rs25487 genotype is closely related to treatment outcomes of oxaliplatin plus capecitabine chemotherapy in patients with advanced gastric cancer.Testing for XRCC1 rs25487 genotype may allow identification of patients who will benefit from chemotherapy.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ ALSAGABY S,AHMED AA,RASHEED Z,et al.Association of genetic polymorphisms in DNA repair genes ERCC2 Asp312Asn (rs1799793),ERCC2 Lys 751 Gln (rs13181),XRCC1 Arg399 Gln (rs25487) and XRCC3 Thr 241Met (rs861539) with the susceptibility of lung cancer in Saudi population［J］.Nucleosides Nucleotides Nucleic Acids,2022,41(5-6):530-554.
［3］ SAAD AM,ABDEL-MEGIED AES,ELBAZ RA,et al.Genetic variants of APEX1 p.Asp148Glu and XRCC1 p.Gln399Arg with the susceptibility of hepatocellular carcinoma［J］.J Med Virol,2021,93(11):6278-6291.
［4］ RAJAGOPAL T,SESHACHALAM A,RATHNAM KK,et al.DNA repair genes hOGG1,XRCC1 and ERCC2 polymorphisms and their molecular mapping in breast cancer patients from India［J］.Mol Biol Rep,2020,47(7):5081-5090.
［5］ HOSSEINI SM,MOHAMMADIASL J,TALAIEZADEH A,et al.Influence of two DNA repair pathway polymorphisms in colorectal cancer risk in southwest iran［J］.Asian Pac J Cancer Prev,2020,21(7):1919-1924.
［6］ CHEN J,WANG H,LI Z.Association between polymorphisms of X-ray repair cross complementing group 1 gene and pancreatic cancer risk:a systematic review with Meta-analysis［J］.Pathol Oncol Res,2019,25(3):897-904.
［7］ YANG W,LIU W,ZHU L,et al.Association between the XRCC1,GSTM1,and GSTT1 polymorphisms in model of thyroid cancer:A Meta-analysis［J］.HormMetab Res,2023,55(9):625-633.
［8］ DATKHILE KD,DURGAWALE PP,PATIL MN,et al.Impact of polymorphism in base excision repair and nucleotide excision repair genes and risk of cervical cancer:a case-control study［J］.Asian Pac J Cancer Prev,2022,23(4):1291-1300.
［9］ DAS AP,SAINI S,TYAGI S,et al.Elucidation of increased cervical cancer risk due to polymorphisms in XRCC1 (R399Q and R194W),ERCC5 (D1104H),and NQO1 (P187S)［J］.Reprod Sci,2023,30(4):1118-1132.
［10］ CHEN L,LIU MM,LIU H,et al.ERCC1 and XRCC1 but not XPA single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma［J］.Onco Targets Ther,2016,9:7019-7028.
［11］ ZHANG N,OUYANG Y,CHANG J,et al.Pharmacogenetic association between XRCC1 polymorphisms and response to platinum-based chemotherapy in Asian patients with NSCLC:A Meta-analysis［J］.Biomed Res Int,2020,2020:3520764.
［12］ ABBAS M,KUSHWAHA VS,SRIVASTAVA K,et al.Understanding role of DNA repair and cytochrome p-450 gene polymorphisms in cervical cancer patient treated with concomitant chemoradiation［J］.Br J Biomed Sci,2022,79:10120.
［13］ LIBLAB S,VUSURATANA A,AREEPIUM N.ERCC1,XRCC1,and GSTP1 polymorphisms and treatment outcomes of advanced epithelial ovarian cancer patients treated with platinum-based chemotherapy［J］.Asian Pac J Cancer Prev,2020,21(7):1925-1929.
［14］ SALIMZADEH H,LINDSKOG EB,GUSTAVSSON B,et al.Association of DNA repair gene variants with colorectal cancer:risk,toxicity,and survival［J］.BMC Cancer,2020,20(1):409.
［15］ DHANGAR S,SHANBHAG V,SHANMUKHAIAH C,et al.Lack of association between functional polymorphism of DNA repair genes (XRCC1,XPD) and clinical response in Indian chronic myeloid leukemia patients［J］.Mol Biol Rep,2019,46(5):4997-5003.
［16］ PUTTHANACHOTE N,PROMTHET S,SUWANRUNGRUAN K,et al.XRCC1 gene polymorphism,clinicopathological characteristics and stomach cancer survival in Thailand［J］.Asian Pac J Cancer Prev,2015,16(14):6111-6116.
［17］ JIN EH,KIM J,LEE SI,et al.Association between polymorphisms in APE1 and XRCC1 and the risk of gastric cancer in Korean population［J］.Int J ClinExp Med,2015,8(7):11484-11489.
［18］ GONG H,LI H,ZOU J,et al.The relationship between five non-synonymous polymorphisms within three XRCC genes and gastric cancer risk in a Han Chinese population［J］.Tumour Biol,2016,37(5):5905-5910.
［19］ PARK SR,KONG SY,NAM BH,et al.CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients［J］.Br J Cancer,2011,104(7):1126-1134.
［20］ LIU R,ZHAO X,LIU X,et al.Influences of ERCC1,ERCC2,XRCC1,GSTP1,GSTT1,and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy［J］.Tumour Biol,2016,37(2):1753-1762.

Memo

Memo:

北京市优秀人才培养资助计划（编号：2015000021469G232）

Common functions

Last Update: 1900-01-01